PharmExec Direct: Having trouble viewing the email? Click Here

In this ISSUE

Industry Troubled by Final Obama Budget

Supply Chain Integration or Bust ... or Both

The Digital Marketing Platforms Here to Stay?

Top Feature
Can FDA Control Drug Prices?
FDA approval of generics following the loss of patent protection can send brand prices plummeting. Market approval of additional brands can have a similar effect. But does FDA do enough to facilitate market approval of alternative products? Or do its actions delay market entry of potential competitors. Jill Wechsler reports
... /Read more/
 
Advertisement
The ZS Explorer Study finds that pharma investments in sales force effectiveness boost revenue 1 - 7%. That might not sound like much, but given their size and scale, pharmacos can achieve a substantial return on sales force effectiveness investments. Read the report to see the latest data on pharma sales force effectiveness.
 
Canada
Private Payers in Canada Embrace Product Listing Agreements
Arvind Mani and Sherry O' Quinn outline the prevalence of private payer PLAs in Canada and look at the potential challenges and issues faced by manufacturers in negotiating them
... /Read more/
 
Advertisement
SPEED TO INSIGHT: 4 Strategies you need to maximize the value of your data assets
On Demand
Join Hewlett Packard Enterprise and Linguamatics as they discuss the right questions to ask about your company's analytics capabilities to gain a competitive advantage. Learn more
 
Canada
Canada's Rx&D: Fresh Start for a New Era
Canada's Rx&D recently changed its name—with a mission of bridging the many points of collaboration that drive the process of modern drugs, from discovery to market. William Looney reports
... /Read more/
Europe
Orphans in the Storm
As a European politician attacks abuses of the orphan drug scheme, a new EU report extols its virtues. Reflector asks: in Europe, does the right hand know what the left hand is doing?
... /Read more/
Global
EU–US Data Privacy Concerns Intensify
Reactive, hastily enforced regulations can easily jeopardize the sound conduct of a clinical trial and its data flow, potentially threatening both subject safety and data quality. Susan Shelby reports
... /Read more/
 
Calendar
/ March 15–17: eyeforpharma 2016 /
Barcelona, Spain
/ March 22–23: 9th Annual Oncology Commercialization and Market Access /
San Francisco, CA.
/ April 18–19: IRT Europe — Interactive Response Technologies in Clinical Trials /
Brussels, Belgium
/ June 21–22: Patient Engagement Solutions Summit /
Philadelphia, PA.
/ August 15–17: 10th Annual Forum on Transparency and Aggregate Spend /
Washington, DC.
 
Industry update
//John Temperato joined Melinta Therapeutics (New Haven, CT) as President and Chief Operating Officer.//GA Communication Group (Chicago, IL) announced its rebirth as Sandbox. Sandbox’s 350 employees will be based in seven offices throughout the US and Canada.//MRIGlobal (Kansas City, MO) announced that Steve Phillips joined the as Vice President of Sales and Marketing.//Kantar Health (New York, NY) announced that Stephen Potts has been named Managing Director of Kantar Health UK. The company also promoted Michel Murino to the newly created role of chief executive officer for Kantar Health Europe.//
 
advertise with us / print subscribe / digital subscribe / visit pharmexec.com